Harrow (HROW) introduced Vevye Access for All, an initiative which is now available through its PhilRx specialty pharmacy partner, guarantees access to Vevye 0.1% for eligible patients and health plans for $59, ensuring that every patient can affordably start treatment without delay.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- HROW Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Harrow executes five-year supply, development agreement for Triesence
- Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls
- Harrow initiated with a Buy at H.C. Wainwright
- Harrow price target lowered to $58 from $65 at Craig-Hallum